https://www.selleckchem.com/ALK.html
001 μM), which targets the MAPK pathway most often activated in human cancers. The coupled intercalation of UA and trametinib (21 molar ratio) into vesicles causes further structural advantageous molecular interactions, promoting the formation of small vesicles. The high druglipid molar ratio (~0.5) in the novel type of co-delivery vesicles enables their direct medical application, possibly also overcoming the multidrug resistance effect.The open border between non-living and living matter, suggested by increasingly emerging fields of nanoscience in
Curtir
Comentario
Compartilhar
